Follow
Enrico Pesenti
Enrico Pesenti
CEO, Accelera
Verified email at accelera.org - Homepage
Title
Cited by
Cited by
Year
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni, P Magni, C Cammia, G De Nicolao, V Croci, E Pesenti, ...
Cancer research 64 (3), 1094-1101, 2004
5142004
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer
TJ Abrams, LJ Murray, E Pesenti, V Walker Holway, T Colombo, LB Lee, ...
Molecular cancer therapeutics 2 (10), 1011-1021, 2003
3232003
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
P Carpinelli, R Ceruti, ML Giorgini, P Cappella, L Gianellini, V Croci, ...
Molecular cancer therapeutics 6 (12), 3158-3168, 2007
2682007
Polymer-bound paclitaxel derivatives
N Mongelli, F Angelucci, E Pesenti, A Suarato, G Biasoli
US Patent 5,362,831, 1994
238*1994
1, 4, 5, 6-tetrahydropyrrolo [3, 4-c] pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile
D Fancelli, J Moll, M Varasi, R Bravo, R Artico, D Berta, S Bindi, ...
Journal of medicinal chemistry 49 (24), 7247-7251, 2006
2302006
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsPreclinical Characterization of Entrectinib
E Ardini, M Menichincheri, P Banfi, R Bosotti, C De Ponti, R Pulci, ...
Molecular cancer therapeutics 15 (4), 628-639, 2016
2262016
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
A Montagnoli, B Valsasina, V Croci, M Menichincheri, S Rainoldi, ...
Nature chemical biology 4 (6), 357-365, 2008
2142008
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations …
A Gontarewicz, S Balabanov, G Keller, R Colombo, A Graziano, E Pesenti, ...
Blood, The Journal of the American Society of Hematology 111 (8), 4355-4364, 2008
2122008
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity
C Soncini, P Carpinelli, L Gianellini, D Fancelli, P Vianello, L Rusconi, ...
Clinical Cancer Research 12 (13), 4080-4089, 2006
1942006
Polymer-bound camptothecin: initial biodistribution and antitumour activity studies
VR Caiolfa, M Zamai, A Fiorino, E Frigerio, C Pellizzoni, R d’Argy, ...
Journal of controlled release 65 (1-2), 105-119, 2000
1852000
Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase
R Colombo, M Caldarelli, M Mennecozzi, ML Giorgini, F Sola, P Cappella, ...
Cancer research 70 (24), 10255-10264, 2010
1792010
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding
P Pevarello, MG Brasca, R Amici, P Orsini, G Traquandi, L Corti, C Piutti, ...
Journal of medicinal chemistry 47 (13), 3367-3380, 2004
1672004
Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs …
M Menichincheri, E Ardini, P Magnaghi, N Avanzi, P Banfi, R Bossi, ...
Journal of medicinal chemistry 59 (7), 3392-3408, 2016
1662016
Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity
E Pesenti, F Sola, N Mongelli, M Grandi, F Spreafico
British journal of cancer 66 (2), 367-372, 1992
1601992
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin
M Broggini, HM Coley, N Mongelli, E Pesenti, MD Wyatt, JA Hartley, ...
Nucleic Acids Research 23 (1), 81-87, 1995
1261995
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization
P Pevarello, MG Brasca, P Orsini, G Traquandi, A Longo, M Nesi, F Orzi, ...
Journal of medicinal chemistry 48 (8), 2944-2956, 2005
1222005
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
E Ardini, R Bosotti, AL Borgia, C De Ponti, A Somaschini, R Cammarota, ...
Molecular oncology 8 (8), 1495-1507, 2014
1192014
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
P Marzola, A Degrassi, L Calderan, P Farace, E Nicolato, C Crescimanno, ...
Clinical cancer research 11 (16), 5827-5832, 2005
1182005
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model
P Marzola, A Degrassi, L Calderan, P Farace, C Crescimanno, E Nicolato, ...
Clinical cancer research 10 (2), 739-750, 2004
1092004
Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease
E Radaelli, R Ceruti, V Patton, M Russo, A Degrassi, V Croci, F Caprera, ...
F. Hernandez 24 (7), 879-891, 2009
1072009
The system can't perform the operation now. Try again later.
Articles 1–20